Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

West Nile virus vaccine.

T P Monath1, J Arroyo, C Miller

  • 1Acambis Inc., 38 Sidney Street, Cambridge, Massachusetts 02139, USA. tom.monath@acambis.com

Current Drug Targets. Infectious Disorders
|November 29, 2002
PubMed
Summary

West Nile encephalitis is an emerging disease. A novel ChimeriVax vaccine approach using yellow fever 17D as a vector offers rapid development for West Nile virus (WNV) protection in humans and animals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensory gating in a computer model of the CA3 neural network of the hippocampus.

Biological psychiatry·1996
Same author

Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model.

Archives of general psychiatry·1996
Same author

Iatrogenic scald burn: a consequence of institutional infection control measures.

Pediatrics·1996
Same author

Social skills training for drug prevention in high-risk female adolescents.

Preventive medicine·1996
Same author

Reconstitution of mammalian pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase complexes: analysis of protein X involvement and interaction of homologous and heterologous dihydrolipoamide dehydrogenases.

The Biochemical journal·1996
Same author

Nonequilibrium gating and voltage dependence of the ClC-0 Cl- channel.

The Journal of general physiology·1996

Area of Science:

  • Virology
  • Vaccinology
  • Epidemiology

Background:

  • West Nile encephalitis has emerged as a significant human and veterinary disease in Europe and North America.
  • West Nile virus (WNV), a mosquito-borne flavivirus, has established in North America and is expected to spread geographically.
  • The emergence of WNV necessitates the development of effective vaccines for both human and animal populations.

Purpose of the Study:

  • To present the rationale for developing human and veterinary vaccines against West Nile encephalitis.
  • To describe a novel ChimeriVax technology for the rapid development of a live, attenuated West Nile virus vaccine.
  • To review other vaccine development approaches for West Nile encephalitis.

Main Methods:

  • Utilizing the ChimeriVax technology, which employs the yellow fever 17D vaccine as a live vector.
  • Employing infectious clone technology to replace specific genes (prM and E) of the yellow fever 17D vector with those from West Nile virus.
  • Developing a chimeric virus that expresses West Nile virus antigens while retaining yellow fever 17D's replication efficiency.

Main Results:

  • The ChimeriVax technology is applicable to developing vaccines against all flaviviruses, with related products nearing clinical trials.
  • The resulting chimeric West Nile virus vaccine candidate contains protective antigens and is expected to allow for clinical trials by mid-2002.
  • This approach facilitates the rapid development of a molecularly-defined, live, attenuated West Nile vaccine.

Conclusions:

  • The ChimeriVax technology provides a well-suited platform for the rapid development of a West Nile virus vaccine.
  • The development of a West Nile virus vaccine is crucial given the disease's emergence in humans, horses, and wildlife.
  • This novel approach holds promise for controlling West Nile encephalitis through timely vaccine availability.

Related Experiment Videos